Fibrobiologics, INC. (FBLG) — SEC Filings

Overview

Fibrobiologics, INC. (FBLG) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Dec 29, 2025: FibroBiologics, Inc. (FBLG) is calling a Special Meeting of Stockholders on February 20, 2026, to address critical corporate actions. The primary proposal is to approve a reverse stock split of its common and preferred stock at a ratio between 1-for-5 and 1-for-30, aimed at potentially boosting its

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 6 bearish, 44 neutral. The dominant filing sentiment for Fibrobiologics, INC. is neutral.

Filing Type Overview

Fibrobiologics, INC. (FBLG) has filed 4 DEF 14A, 4 S-1, 26 8-K, 6 10-Q, 2 10-K, 8 S-1/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• FibroBiologics Seeks Reverse Split, Share Issuance Approvals — DEF 14A · Dec 29, 2025 Risk: high
  FibroBiologics, Inc. (FBLG) is calling a Special Meeting of Stockholders on February 20, 2026, to address critical corporate actions. The primary proposal is to
• FibroBiologics Registers 22.5M Shares for Resale, Eyes $7.5M from Warrants — S-1 · Dec 23, 2025 Risk: high
  FibroBiologics, Inc. (FBLG) filed an S-1 to register the resale of up to 22,494,434 shares of common stock by selling stockholders, primarily stemming from rece
• FibroBiologics Seeks Reverse Split, Massive Share Issuances — DEF 14A · Dec 18, 2025 Risk: high
  FibroBiologics, Inc. (FBLG) is seeking stockholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30, aimed at maintaining Nasdaq listi
• FibroBiologics Files 8-K: Material Agreement, Equity Sales — 8-K · Dec 15, 2025 Risk: medium
  FibroBiologics, Inc. filed an 8-K on December 15, 2025, reporting on events that occurred on December 14, 2025. The filing indicates a material definitive agree
• 8-K Filing — 8-K · Nov 25, 2025
• 8-K Filing — 8-K · Nov 19, 2025
• FibroBiologics' Losses Double Amid Soaring R&D, Cash Dwindles — 10-Q · Oct 31, 2025 Risk: high
  FibroBiologics, Inc. (FBLG) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $15.402 million, a substantial ri
• FibroBiologics Faces Delisting Concerns — 8-K · Aug 8, 2025 Risk: high
  FibroBiologics, Inc. filed an 8-K on August 8, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the effect
• FibroBiologics Posts Zero Revenue, Deepens Losses Amid Equity Raises — 10-Q · Jul 31, 2025 Risk: high
  FibroBiologics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercialization stage. The company incurred
• FibroBiologics Reports Unregistered Equity Sales — 8-K · Jul 18, 2025 Risk: medium
  FibroBiologics, Inc. filed an 8-K on July 18, 2025, reporting unregistered sales of equity securities that occurred on June 20, 2025. The filing details the com
• FibroBiologics Faces Listing Rule Issues — 8-K · Jul 3, 2025 Risk: high
  FibroBiologics, Inc. filed an 8-K on July 3, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of
• FibroBiologics Files 8-K: Agreements, Obligations, Equity Sales — 8-K · Jun 16, 2025 Risk: medium
  On June 16, 2025, FibroBiologics, Inc. filed an 8-K report detailing a material definitive agreement, the creation of a direct financial obligation, unregistere
• FibroBiologics Files 8-K on Shareholder Votes & Bylaws — 8-K · Jun 13, 2025 Risk: low
  FibroBiologics, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders and amendments to its articles of incorporation
• FibroBiologics Appoints New CMO, Adds Directors — 8-K · Jun 9, 2025 Risk: medium
  FibroBiologics, Inc. announced on June 9, 2025, the appointment of Dr. Robert L. Johnson as Chief Medical Officer and the election of Dr. Johnson and Ms. Karen
• FibroBiologics Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: low
  FibroBiologics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, located at 455 E. Medical Center Blvd, Suite 300, Houston, TX, reported i
• FibroBiologics Appoints New CEO, Adds Director, Restructures Executive Roles — 8-K · May 5, 2025 Risk: medium
  FibroBiologics, Inc. announced on May 2, 2025, a series of executive and board changes. Dr. Jonathan Webb has been appointed as Chief Executive Officer, and Dr.
• FibroBiologics Files 2024 Proxy Statement — DEF 14A · Apr 23, 2025 Risk: low
  FibroBiologics, Inc. filed its definitive proxy statement (DEF 14A) on April 23, 2025, for the fiscal year ending December 31, 2024. The filing details informat
• FibroBiologics Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  FibroBiologics, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, located in Houston, TX, operates
• FibroBiologics Files 8-K on Equity Sales — 8-K · Feb 7, 2025 Risk: medium
  On January 7, 2025, FibroBiologics, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also included financial statements an
• FibroBiologics Appoints New CMO, Adds Director — 8-K · Jan 24, 2025 Risk: medium
  FibroBiologics, Inc. announced on January 23, 2025, the appointment of Dr. Jonathan L. R. Roth as Chief Medical Officer and the election of Dr. David M. Epstein
• FibroBiologics Files S-1/A for IPO — S-1/A · Jan 10, 2025 Risk: medium
  FibroBiologics, Inc. filed an S-1/A amendment on January 10, 2025, for its initial public offering. The company, incorporated in Delaware, is seeking to registe
• FibroBiologics Files 8-K: Agreements, Equity, and Personnel Changes — 8-K · Dec 31, 2024 Risk: medium
  On December 27, 2024, FibroBiologics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on th
• FibroBiologics Files S-1 for Public Offering — S-1 · Dec 30, 2024 Risk: medium
  FibroBiologics, Inc. filed an S-1 registration statement with the SEC on December 30, 2024, to register securities under the Securities Act of 1933. The company
• FibroBiologics Files 8-K: Agreements, Obligations, and Equity Sales — 8-K · Dec 23, 2024 Risk: medium
  On December 20, 2024, FibroBiologics, Inc. entered into a material definitive agreement related to a direct financial obligation. The company also reported on t
• FibroBiologics Files 8-K: Agreements, Equity Sales — 8-K · Dec 20, 2024 Risk: medium
  On December 19, 2024, FibroBiologics, Inc. entered into a material definitive agreement with an undisclosed party. The company also reported on the termination
• FibroBiologics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  FibroBiologics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial position and operational updates. Key f
• FibroBiologics Board Shake-up: New Director Elected, Officer Compensation Noted — 8-K · Oct 29, 2024 Risk: medium
  FibroBiologics, Inc. announced on October 25, 2024, a change in its board of directors. Specifically, the company reported the departure of Director Dr. Jonatha
• FibroBiologics, Inc. Enters Material Definitive Agreement — 8-K · Sep 24, 2024 Risk: medium
  On September 19, 2024, FibroBiologics, Inc. entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement, its
• FibroBiologics Files 8-K on Corporate Actions — 8-K · Aug 28, 2024 Risk: low
  FibroBiologics, Inc. filed an 8-K on August 27, 2024, reporting on several key corporate actions. These include amendments to its articles of incorporation or b
• FibroBiologics Files 8-K for Equity Sale — 8-K · Aug 27, 2024 Risk: medium
  FibroBiologics, Inc. announced on August 26, 2024, the unregistered sale of equity securities. The company filed an 8-K report detailing this event, which also
• FibroBiologics Files 10-Q, Details Preferred Stock — 10-Q · Aug 7, 2024 Risk: medium
  FibroBiologics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, located in Houston, TX, operates in the Pharmaceutical Preparations sector
• FibroBiologics Files Definitive Proxy Statement — DEF 14A · Jul 8, 2024 Risk: low
  FibroBiologics, Inc. filed a definitive proxy statement (DEF 14A) on July 8, 2024. The filing pertains to the company's annual meeting and related matters. The
• FibroBiologics Relocates Offices, Updates Contact Info — 8-K · Jun 27, 2024 Risk: low
  FibroBiologics, Inc. filed an 8-K on June 27, 2024, reporting a change in its principal executive offices to 455 E. Medical Center Blvd., Suite 300, Houston, Te
• FibroBiologics Files S-1 for Public Offering — S-1 · Jun 18, 2024 Risk: medium
  FibroBiologics, Inc. filed an S-1 registration statement on June 18, 2024, to register securities under the Securities Act of 1933. The company, incorporated in
• FibroBiologics Files S-1/A Amendment for IPO — S-1/A · Jun 4, 2024 Risk: medium
  FibroBiologics, Inc. filed an S-1/A amendment on June 4, 2024, for its initial public offering. The company, incorporated in Delaware, is in the pharmaceutical
• FibroBiologics Files Amendment to S-1 Registration Statement — S-1/A · May 15, 2024 Risk: low
  FibroBiologics, Inc. (FBLG) filed a Amended IPO Registration (S-1/A) with the SEC on May 15, 2024. FibroBiologics, Inc. filed an amendment (Amendment No. 1) to
• FibroBiologics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: low
  FibroBiologics, Inc. (FBLG) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. FibroBiologics, Inc. filed a 10-Q report for the period ending March 3
• FibroBiologics Files 8-K Report — 8-K · Apr 26, 2024 Risk: low
  On April 26, 2024, FibroBiologics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific mate
• FibroBiologics Files S-1/A Amendment — S-1/A · Mar 26, 2024 Risk: low
  FibroBiologics, Inc. (FBLG) filed a Amended IPO Registration (S-1/A) with the SEC on March 26, 2024. FibroBiologics, Inc. filed an S-1/A amendment on March 26,
• FibroBiologics, Inc. Files S-1/A Amendment — S-1/A · Mar 15, 2024 Risk: low
  FibroBiologics, Inc. (FBLG) filed a Amended IPO Registration (S-1/A) with the SEC on March 15, 2024. FibroBiologics, Inc. filed an S-1/A amendment on March 15,
• FibroBiologics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk:
  FibroBiologics, Inc. (FBLG) filed a Annual Report (10-K) with the SEC on February 29, 2024. FibroBiologics, Inc. filed its annual report on Form 10-K for the fi
• FibroBiologics Files 8-K on Other Events and Financial Exhibits — 8-K · Feb 20, 2024 Risk: low
  FibroBiologics, Inc. filed an 8-K on February 20, 2024, reporting on "Other Events" and "Financial Statements and Exhibits." The filing indicates a current repo
• FibroBiologics Files 8-K for Unspecified Events and Exhibits — 8-K · Feb 14, 2024 Risk: low
  FibroBiologics, Inc. filed an 8-K on February 14, 2024, reporting an earliest event date of February 13, 2024. The filing indicates 'Other Events' and 'Financia
• FibroBiologics, Inc. Files S-1 Registration Statement — S-1 · Feb 12, 2024 Risk: medium
  FibroBiologics, Inc. (FBLG) filed a IPO Registration (S-1) with the SEC on February 12, 2024. FibroBiologics, Inc. filed an S-1 registration statement with the
• FibroBiologics Files 8-K, Confirms Emerging Growth Status — 8-K · Feb 8, 2024 Risk: low
  FibroBiologics, Inc. filed an 8-K on February 8, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits'. This filing indicates that the compan
• FibroBiologics 8-K: Emerging Growth Co. Opts Out of Accounting Grace Period — 8-K · Feb 6, 2024
  FibroBiologics Inc. filed an 8-K on February 6, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates that the company i
• FibroBiologics Confirms Emerging Growth Company Status in 8-K — 8-K · Feb 2, 2024
  FibroBiologics Inc. filed an 8-K on February 2, 2024, reporting an event that occurred on January 31, 2024. The filing indicates that FibroBiologics is an emerg
• FibroBiologics Inc. Files Amendment to S-1 Registration Statement — S-1/A · Jan 24, 2024 Risk: low
  FibroBiologics Inc. (FBLG) filed a Amended IPO Registration (S-1/A) with the SEC on January 24, 2024. FibroBiologics, Inc. filed an amendment (S-1/A) to its reg
• FibroBiologics Inc. Files Amendment 6 to S-1 Registration Statement — S-1/A · Jan 22, 2024 Risk: low
  FibroBiologics Inc. (FBLG) filed a Amended IPO Registration (S-1/A) with the SEC on January 22, 2024. FibroBiologics, Inc. filed Amendment No. 6 to its Form S-1
• FibroBiologics Inc. Files Amendment No. 5 to S-1 Registration Statement — S-1/A · Jan 12, 2024 Risk: medium
  FibroBiologics Inc. (FBLG) filed a Amended IPO Registration (S-1/A) with the SEC on January 12, 2024. FibroBiologics, Inc. filed Amendment No. 5 to its Form S-1

Risk Profile

Risk Assessment: Of FBLG's 45 recent filings, 7 were flagged as high-risk, 22 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Fibrobiologics, INC.'s most recent 10-Q filing (Oct 31, 2025):

• Net Income: -$15.402M
• Cash Position: $4.867M
• Total Assets: $8.744M
• Total Debt: $4.573M

Key Executives

• Pete O'Heeron
• Ruben A. Garcia
• Chief Executive Officer
• Dr. Robert L. Johnson
• Ms. Karen L. Smith
• Jonathan Webb
• Michael J. McVoy
• Jeffrey S. Miller
• Hamid Khoja
• Dr. Jonathan L. R. Roth
• Dr. David M. Epstein
• Pete O’Heeron
• Brian Fenske
• Dr. Michael J. Yaszemski

Industry Context

FibroBiologics operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often rely on significant funding rounds and strategic corporate actions to advance research, development, and commercialization. The need for Nasdaq compliance highlights the pressure to maintain a certain market valuation and investor perception.

Top Tags

FibroBiologics (9) · SEC Filing (8) · equity-sale (7) · S-1/A (6) · Biotechnology (5) · 10-Q (5) · IPO (5) · regulatory-filing (4) · material-definitive-agreement (4) · corporate-governance (4)

Key Numbers

• Minimum reverse stock split ratio: 1-for-5 — Proposed amendment to Certificate of Incorporation
• Maximum reverse stock split ratio: 1-for-30 — Proposed amendment to Certificate of Incorporation
• Shares issuable from November 18 SPA: 12,110,203 — Subject to Nasdaq Listing Rule 5635(d) approval
• Shares issuable from November 24 SPA: 4,477,614 — Subject to Nasdaq Listing Rule 5635(d) approval
• Shares issuable from November 24 Engagement Letter: 313,433 — Subject to Nasdaq Listing Rule 5635(d) approval
• Shares issuable from December SPA: 5,227,275 — Subject to Nasdaq Listing Rule 5635(d) approval
• Shares issuable from December Engagement Letter: 365,909 — Subject to Nasdaq Listing Rule 5635(d) approval
• Common stock shares outstanding: 66,519,722 — As of December 26, 2025 record date
• Series C Preferred Stock shares outstanding: 2,500 — Held by Pete O'Heeron
• Percentage of total votes controlled by Board via Series C Preferred Stock: 32.8% — Represents 32,500,000 votes
• Shares of Common Stock: 22,494,434 — Maximum shares registered for resale by Selling Stockholders, indicating potential dilution.
• Potential Gross Proceeds: $7.5M — Aggregate gross proceeds FibroBiologics could receive if all warrants are exercised for cash, crucial for funding operations.
• Last Reported Stock Price: $0.2596 — Closing price on December 22, 2025, which is below most warrant exercise prices, impacting likelihood of cash exercise.
• November 19 Warrant Exercise Price: $0.3303 — Exercise price for 12,110,203 shares, higher than current market price.
• November 25 Warrant Exercise Price: $0.335 — Exercise price for 4,477,614 shares, higher than current market price.

Forward-Looking Statements

• {"claim":"FibroBiologics, Inc. will proceed with a public offering of its securities.","entity":"FibroBiologics, Inc.","targetDate":"2024-12-31","confidence":"medium"}
• {"claim":"The company will face significant regulatory scrutiny given its pharmaceutical industry classification.","entity":"FibroBiologics, Inc.","targetDate":"2025-12-31","confidence":"high"}
• {"claim":"FibroBiologics will continue to operate with reduced SEC reporting requirements due to its emerging growth company status.","entity":"FibroBiologics, Inc.","targetDate":"2025-02-08","confidence":"high"}

Related Companies

FBIO

Frequently Asked Questions